Compare Domino's Pizza, Inc. (DPZ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Domino's Pizza, Inc. trades at $298 (market cap $9.74B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Domino's Pizza, Inc. is the larger of the two by market cap, and Domino's Pizza, Inc. pays a 2.69% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| DPZ | TVTX | |
|---|---|---|
Market Cap | $9.74B | $4.88B |
Volume | 2,053,142 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $67.52 |
52-Week Low | $282.89 | $26.79 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $14.63B | $5.01B |
Dividend Yield | 2.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $295.89, down 4.83% with mixed technical signals but strong fundamentals. The stock shows a bullish overall technical signal despite recent price weakness, while fundamentals reveal consistent revenue growth to $4.94 billion in 2025 and healthy net margins of 11.86%. Recent earnings show improvement with a Q3 2026 beat after three consecutive misses, though the company faces high debt levels and flat dividend growth.
The outlook remains cautiously optimistic with a $368 consensus price target representing 24% upside potential. Key opportunities include sustained profitability and market leadership, while risks center on high leverage and competitive pressures. Analyst sentiment leans bullish with 50% buy ratings, but investors should monitor debt management and same-store sales trends.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
